APA (7th ed.) Citation

Martin-Broto, J., Valverde, C., Hindi, N., Vincenzi, B., Martinez-Trufero, J., Grignani, G., . . . Martinez-Marin, V. (2023). REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. BMC.

Chicago Style (17th ed.) Citation

Martin-Broto, Javier, et al. REGISTRI: Regorafenib in First-line of KIT/PDGFRA Wild Type Metastatic GIST: A Collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) Phase II Trial. BMC, 2023.

MLA (9th ed.) Citation

Martin-Broto, Javier, et al. REGISTRI: Regorafenib in First-line of KIT/PDGFRA Wild Type Metastatic GIST: A Collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) Phase II Trial. BMC, 2023.